The Fool’s Game That Became Standard Practice: Perfusion, the ATF, and What Changed – Part 2
How do you know when your biotech startup is ready to sell—before the product is “perfect”?
The Fool’s Game That Became Standard Practice: Perfusion, the ATF, and What Changed – Part 1
Most bioprocess innovation is dismissed as a “fool’s game”—until the skeptics are proven wrong.
Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 2
What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?
Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 1
What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?
Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 2
Securing capital for biotech innovation has never been more challenging—or more crucial.
Why Strong Science Isn’t Enough to Get Funded: What Investors Actually Look For – Part 1
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.
Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered – Part 2
Complex automation often arrives wrapped in hype, but the reality is more nuanced.
Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered – Part 1
Are you struggling with automation projects that spiral into unnecessary complexity or fail to solve the real problem in bioprocessing?
From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success – Part 2
Biologics manufacturing success is built—not salvaged—from day one. Overlook CMC fundamentals, and you’re architecting your own failure.
From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success – Part 1
How solid is your CMC foundation—and what happens if it cracks under pressure?